Document 0569
 DOCN  M9480569
 TI    Does intravenous immune globulin have a role in HIV-infected patients?
 DT    9410
 AU    Yap PL; Edinburgh & South East Scotland Blood Transfusion Service, UK.
 SO    Clin Exp Immunol. 1994 Jul;97 Suppl 1:59-67. Unique Identifier :
       AIDSLINE MED/94306770
 AB    The main immunological abnormality in human immunodeficiency virus
       (HIV)-infected patients, and particularly those with the acquired immune
       deficiency syndrome (AIDS), is a deficiency in cellular immunity.
       However, symptomatic HIV-infected children also have evidence of
       deficiency of specific antibody synthesis, and intravenous immune
       globulin (IVIG) preparations in doses of 0.2-0.4 g/kg every 2-4 weeks
       have been shown to reduce the incidence of respiratory infections. IVIG
       therapy may also reduce the mortality and incidence of bacterial
       infections in adults but further studies are required. In addition,
       high-dose IVIG therapy (1-2 g/kg over 2-5 days) produces increased
       platelet counts in patients with idiopathic thrombocytopenic purpura
       (ITP) associated with HIV infection. Finally, IVIG therapy may have a
       role in HIV-infected patients suffering from severe parvovirus B19 or
       measles infection, or in patients suffering from autoimmune disorders
       where high-dose IVIG therapy has been shown to be efficacious.
 DE    Adult  AIDS-Related Opportunistic Infections/PREVENTION & CONTROL/
       THERAPY  Child  Clinical Trials  Human  HIV
       Infections/COMPLICATIONS/IMMUNOLOGY/*THERAPY  Immunoglobulins,
       Intravenous/*THERAPEUTIC USE  Purpura, Thrombocytopenic,
       Idiopathic/COMPLICATIONS/THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).